SciBase Adjusts TO 2 Warrants Following Latest Rights Issue Announcement

STOCKHOLM, Oct. 7, 2026 – In a recent announcement, SciBase Holding AB clarified adjustments made to the warrants of series TO 2, originally issued alongside the company’s capital raise declared in April 2024. Following the rights issue resolved on September 3, 2026, the company recalculated the number of shares each warrant entitles holders to subscribe for, as well as the new subscription price.

As a result of this recalculation, it has been determined that each warrant of series TO 2 now allows the holder to subscribe for 0.01 shares. Additionally, the subscription price is set at SEK 37.47 per share. This revised subscription allowance will be effective from April 3, 2029, until April 17, 2029.

The recalibrated pricing and share subscription figures aim to reflect the recent changes in shares available due to the rights issue. The updated terms and conditions for these warrants, including guidelines for future adjustments resulting from potential share issues, are accessible via SciBase’s official website. This clarity is crucial for investors, providing a transparent view of what the adjustments mean for their holdings and investment strategies.

For anyone needing further information regarding these changes or seeking clarification on the rights issues, Michael Colérus, CEO of SciBase, is available for inquiries. He can be reached at +46703413472 or via email at [email protected]

About SciBase
SciBase is recognized as a cutting-edge medical technology firm focusing on early detection and preventative measures in dermatology. Their flagship product, Nevisense, stands out as a unique, AI-driven platform that harnesses advanced electrical impedance spectroscopy (EIS) technology, significantly boosting diagnostic accuracy and enabling proactive skin health management.

The essence of SciBase's mission lies in reducing patient suffering and enhancing clinicians' ability to make timely interventions that can ultimately save lives and lower healthcare expenditures. Founded on over two decades of research conducted at the esteemed Karolinska Institute in Stockholm, SciBase has firmly established itself as a pioneer in dermatological advancements.

Since June 2, 2015, the company has been listed on the Nasdaq First North Growth Market exchange and is under the guidance of its Certified Adviser, DNB Carnegie Investment Bank AB (publ). For more insight into their latest developments, financial disclosures, and press releases, visit www.scibase.com or check their investor relation page at http://investors.scibase.se/en/pressreleases.

This update is crucial for current and prospective investors as it highlights the company's ongoing commitment to transparency and financial integrity. Continuing to engage with shareholders and stakeholders ensures that SciBase remains transparent in its operations, especially in light of its recent growth and capital strategies.

Whether existing investors or new entrants within the market, keeping abreast of these changes will provide clarity on potential future returns linked with the warrants of series TO 2. As SciBase continues to innovate and expand its reach within medical technology and dermatological advancements, such updates will be pivotal in shaping investor expectations and market performance.